If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-14. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
=== Formulations === Metoprolol was synthesized and its activity discovered in 1969. The specific agent in on-market formulations of metoprolol is either metoprolol tartrate or metoprolol succinate, where tartrate is an immediate-release formulation and the succinate is an extended-release formulation (with 100 mg metoprolol tartrate corresponding to 95 mg metoprolol succinate). Metoprolol tartrate was first developed by Novartis and this dosage form received approval in the US in 1978. The extended-release salt, metoprolol succinate was developed by Astra Pharmaceuticals, and received a US patent in 1992.
==== Post-World War II ==== Most modern and currently-issued rations were developed during and after the Cold War. The Soviet Armed Forces issued their personnel a very basic ration of tushonka, bread or crackers, and condensed milk, with little variety. Both the West German Bundeswehr and the East German National People's Army issued 24-hour rations containing four meals each, though their contents and types varied. The U.S. military, initially issuing the canned Meal, Combat, Individual (similar to the C-ration) from the late 1950s through the Vietnam War, developed the Meal, Ready-to-Eat (MRE) in 1983, designed to provide easy-to-prepare individual meals in retort pouches that could last for very long periods of time. The British 24-hour ration gradually advanced from tinned rations to freeze-dried and vacuum-sealed rations. The Russian invasion of Ukraine challenged the ability of Russia to provision its soldiers. In the early days of the conflict in spring 2022, the Russian Ground Forces had to contend with low supplies of rations, which led them to forage for provisions in a manner reminiscent of the practices of ancient armies.
=== Natural fission chain-reactors on Earth === Criticality in nature is uncommon. At three ore deposits at Oklo in Gabon, sixteen sites (the so-called Oklo Fossil Reactors) have been discovered at which self-sustaining nuclear fission took place approximately 2 billion years ago. French physicist Francis Perrin discovered the Oklo Fossil Reactors in 1972, but it was postulated by Paul Kuroda in 1956. Large-scale natural uranium fission chain reactions, moderated by normal water, had occurred far in the past and would not be possible now. This ancient process was able to use normal water as a moderator only because 2 billion years before the present, natural uranium was richer in the shorter-lived fissile isotope 235U (about 3%), than natural uranium available today (which is only 0.7%, and must be enriched to 3% to be usable in light-water reactors).
CORD provides a strong common voice to advocate for health policy and a healthcare system that works for those with rare disorders. NORD - National Organization for Rare Disorders (NORD) is an American national non-profit patient advocacy organization that is dedicated to individuals with rare diseases and the organizations that serve them. EURODIS - Rare Diseases Europe (EURODIS) is a unique, non-profit alliance of over 700 rare disease patient organizations across Europe that work together to improve the lives of the 30 million people living with a rare disease in Europe.
Sources: en.wikipedia.org
Pseudoenzymes are variants of enzymes that are catalytically-deficient (usually inactive), meaning that they perform little or no enzyme catalysis. They are believed to be represented in all major enzyme families in the kingdoms of life, where they have important signaling and metabolic functions, many of which are only now coming to light. Pseudoenzymes are becoming increasingly important to analyse, especially as the bioinformatic analysis of genomes reveals their ubiquity. Their important regulatory and sometimes disease-associated functions in metabolic and signalling pathways are also shedding new light on the non-catalytic functions of active enzymes, of moonlighting proteins, the re-purposing of proteins in distinct cellular roles (Protein moonlighting). They are also suggesting new ways to target and interpret cellular signalling mechanisms using small molecules and drugs. The most intensively analyzed, and certainly the best understood pseudoenzymes in terms of cellular signalling functions are probably the pseudokinases, the pseudoproteases and the pseudophosphatases. Recently, the pseudo-deubiquitylases have also begun to gain prominence.
Clinical data management Clinical Quality Management System Clinical trial management system Clinical trial Electronic data capture Electronic Common Technical Document (eCTD) Drug development Stuart Summerhayes, CDM Regulations Procedures Manual, Blackwell Publishing, ISBN 1-4051-0740-5 Tai BC, Seldrup J., A review of software for data management, design and analysis of clinical trials, Ann Acad Med Singap. 2000 Sep;29(5):576-81. Greenes RA, Pappalardo AN, Marble CW, Barnett GO., Design and implementation of a clinical data management system, Comput Biomed Res. 1969 Oct;2(5):469-85. CDMS at Mayo Clinic Association for Clinical Data Management Society for Clinical Data Management French network of Data Managers in Academic biomedical research Data Quality Research Institute Data Security Software for Clinics
== Further reading == Braver, Lee, (2015) "Coin-Operated Doors and God: A Gnostic Reading of Philip K. Dick's Ubik", Extrapolation 56.1, pp. 83–110. https://doi.org/10.3828/extr.2015.6 Fitting, Peter, (1975) "Ubik and the Deconstruction of Bourgeois SF Archived 2020-08-04 at the Wayback Machine", Science-Fiction Studies # 5, 2:1, pp. 47–54. Lem, Stanislaw, (1975) "Science and Reality in Philip K. Dick's Ubik", A Multitude of Visions, ed. Cy Chauvin, Baltimore; T-K Graphics, pp. 35–9. Pagetti, Carlo, (2003) "Ubik uno e trino" [afterword], Philip K. Dick, Ubik, Roma: Fanucci, pp. 253–66. (in Italian) Proietti, Salvatore, (2006) "Vuoti di potere e resistenza umana: Dick, Ubik e l'epica americana", Trasmigrazioni: I mondi di Philip K. Dick, eds. Valerio Massimo De Angelis and Umberto Rossi, Firenze: Le Monnier, pp. 204–16. (in Italian)
"have a sensitivity of at least 80% for detecting a particular psychiatric disorder" "should have a specificity of at least 80% for distinguishing this disorder from other psychiatric or medical disorders" "should be reliable, reproducible, and ideally be noninvasive, simple to perform, and inexpensive" "proposed biomarkers should be verified by 2 independent studies each by a different investigator and different population samples and published in a peer-reviewed journal" The review concluded that although neuroimaging diagnosis may technically be feasible, very large studies are needed to evaluate specific biomarkers which were not available.
The Beattie Ministry was a Ministry of the Government of Queensland, led by Labor Premier Peter Beattie. It commenced on 26 June 1998, thirteen days after the Borbidge Ministry, led by Premier Rob Borbidge of the National Party, was defeated at the 1998 election. It was followed by the Bligh Ministry upon Beattie's retirement as Premier on 13 September 2007.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.